R1	Has_value Arg1:T5 Arg2:T4	
R2	Has_index Arg1:T6 Arg2:T7	
*	OR T2 T3
R3	Has_temporal Arg1:T4 Arg2:T6	
R4	Has_value Arg1:T8 Arg2:T9	
*	OR T11 T14 T12 T13
R5	Subsumes Arg1:T10 Arg2:T11	
R6	Has_qualifier Arg1:T18 Arg2:T16	
R7	Has_qualifier Arg1:T18 Arg2:T17	
R8	Has_value Arg1:T21 Arg2:T20	
R9	Has_value Arg1:T24 Arg2:T25	
R10	Has_value Arg1:T22 Arg2:T23	
*	OR T22 T24
R11	AND Arg1:T19 Arg2:T21	
R12	AND Arg1:T19 Arg2:T22	
R13	Has_qualifier Arg1:T19 Arg2:T26	
T1	Informed_consent 0 100	Provide written, signed and dated informed consent prior to initiating any study-related activities.
T2	Person 102 106	Male
T3	Person 110 116	female
T4	Value 117 133	>18 years of age
T5	Person 130 133	age
T6	Temporal 134 158	at the time of screening
T7	Reference_point 137 158	the time of screening
T8	Measurement 160 186	Fitzpatrick Skin phototype
T9	Value 187 192	IV-VI
T10	Person 194 218	non-white race/ethnicity
T11	Person 253 270	African Americans
T12	Person 272 278	Asians
T13	Person 280 297	Pacific Islanders
T14	Person 302 311	Hispanics
T16	Qualifier 344 355	plaque-type
T17	Qualifier 336 343	chronic
T18	Condition 356 377	psoriasis of the body
T19	Condition 379 395	Plaque psoriasis
T20	Value 401 428	=2% Body Surface Area (BSA)
T21	Measurement 429 440	involvement
T22	Measurement 474 484	PASI Score
T23	Value 485 488	= 2
T24	Measurement 490 508	IGA mod 2011 score
T25	Value 512 524	2 or greater
T26	Qualifier 535 547	scale of 0-4
T28	Pregnancy_considerations 550 878	Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline. While using investigational product and for at least 28 days after last application of investigational product, FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options d
T29	Non-query-able 880 991	Must be in general good health as judged by the Investigator, based on medical history and physical examination
